Inactivation of X-linked tumor suppressor genes in human cancer

Future Oncology

Volumn 8, Issue 4, 2012, Pages 463-481

  Liu, Runhua ^a,b   Kain, Mandy ^a   Wang, Lizhong ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Department of Pharmacology and Toxicology and Mass Spectrometry Core Facility   (United States)

Author keywords

cancer; single hit inactivation; tumor suppressor; X chromosome inactivation; X linked gene

Indexed keywords

ATRX PROTEIN; CD99 ANTIGEN; DYSKERIN; EDA2R PROTEIN; ELF4 PROTEIN; FAM123B PROTEIN; LDOC1 PROTEIN; PHF6 PROTEIN; RETINOBLASTOMA BINDING PROTEIN 7; RIBOSOMAL PROTEIN L1; RIBOSOMAL PROTEIN L10; RPS6KA6 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WTX PROTEIN; ZINC FINGER PROTEIN;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; EPIGENETICS; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; X LINKED TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENES, X-LINKED; HUMANS; NEOPLASMS;

EID: 84860206966     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.26     Document Type: Review

References (214)

1. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68(4), 820-823 (1971).
2. Levine AJ, Finlay CA, Hinds PW. P53 is a tumor suppressor gene. Cell 116(Suppl. 2), S67-S69 (2004).
3. Wang S, Gao J, Lei Q et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4(3), 209-221 (2003). (Pubitemid 37163835)
4. Liu Y, Wang L, Zheng P. X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity. Trends Genet. 26(6), 260-265 (2010).
5. Wang L, Liu R, Li W et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 16(4), 336-346 (2009).
6. Zuo T, Wang L, Morrison C et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129(7), 1275-1286 (2007). (Pubitemid 46970708)
7. Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nat. Rev. Cancer 4(8), 617-629 (2004). (Pubitemid 39025056)
8. Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J. Natl Cancer Inst. 91(4), 339-346 (1999). (Pubitemid 29102333)
9. Liao DJ, Du QQ, Yu BW, Grignon D, Sarkar FH. Novel perspective: focusing on the X chromosome in reproductive cancers. Cancer Invest. 21(4), 641-658 (2003). (Pubitemid 37169566)
10. Pageau GJ, Hall LL, Ganesan S, Livingston DM, Lawrence JB. The disappearing Barr body in breast and ovarian cancers. Nat. Rev. Cancer 7(8), 628-633 (2007). (Pubitemid 47106629)
11. Klein CB, Conway K, Wang XW et al. Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. Science 251(4995), 796-799 (1991). (Pubitemid 21926173)
12. Wang XW, Lin X, Klein CB, Bhamra RK, Lee YW, Costa M. A conserved region in human and Chinese hamster X chromosomes can induce cellular senescence of nickel-transformed Chinese hamster cell lines. Carcinogenesis 13(4), 555-561 (1992).
13. Loupart ML, Adams S, Armour JA, Walker R, Brammar W, Varley J. Loss of heterozygosity on the X chromosome in human breast cancer. Genes Chromosomes Cancer 13(4), 229-238 (1995).
14. Choi C, Kim MH, Juhng SW. Loss of heterozygosity on chromosome XP22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas. J. Korean Med. Sci. 13(3), 311-316 (1998). (Pubitemid 128686081)
15. Yang-Feng TL, Li S, Han H, Schwartz PE. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int. J. Cancer 52(4), 575-580 (1992).
16. Yang-Feng TL, Han H, Chen KC et al. Allelic loss in ovarian cancer. Int. J. Cancer 54(4), 546-551 (1993). (Pubitemid 23188182)
17. Feder M, Liu Z, Apostolou S, Greenberg RE, Testa JR. Loss of chromosomes 1 and X in a renal oncocytoma: implications for a possible pseudoautosomal tumor suppressor locus. Cancer Genet. Cytogenet. 123(1), 71-72 (2000).
18. Buekers TE, Lallas TA, Buller RE. Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer. Gynecol. Oncol. 76(3), 418-422 (2000). (Pubitemid 30131519)
19. Edelson MI, Lau CC, Colitti CV et al. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 16(2), 197-202 (1998). (Pubitemid 28045105)
20. Fujino T, Risinger JI, Collins NK et al. Allelotype of endometrial carcinoma. Cancer Res. 54(16), 4294-4298 (1994). (Pubitemid 24273137)
21. Mitra AB, Murty VV, Li RG, Pratap M, Luthra UK, Chaganti RS. Allelotype analysis of cervical carcinoma. Cancer Res. 54(16), 4481-4487 (1994). (Pubitemid 24273166)
22. Thrash-Bingham CA, Salazar H, Greenberg RE, Tartof KD. Loss of heterozygosity studies indicate that chromosome arm 1p harbors a tumor supressor gene for renal oncocytomas. Genes Chromosomes Cancer 16(1), 64-67 (1996).
23. Rohrbach H, Haas CJ, Baretton GB et al. Microsatellite instability and loss of heterozygosity in prostatic carcinomas: comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. Prostate 40(1), 20-27 (1999). (Pubitemid 29244491)
24. Xu J, Meyers D, Freije D et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. 20(2), 175-179 (1998). (Pubitemid 28455451)
25. Cheng PC, Gosewehr JA, Kim TM et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J. Natl Cancer Inst. 88(8), 510-518 (1996). (Pubitemid 26118721)
26. Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br. J. Cancer 69(3), 429-438 (1994). (Pubitemid 24076457)
27. Dodson MK, Hartmann LC, Cliby WA et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res. 53(19), 4456-4460 (1993). (Pubitemid 23304361)
28. Choi C, Cho S, Horikawa I et al. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer 20(3), 234-242 (1997). (Pubitemid 27484098)
29. Chenevix-Trench G, Kerr J, Hurst T et al. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer 18(2), 75-83 (1997). (Pubitemid 27068905)
30. Sirchia SM, Ramoscelli L, Grati FR et al. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Cancer Res. 65(6), 2139-2146 (2005). (Pubitemid 40490120)
31. Wang N, Cedrone E, Skuse GR, Insel R, Dry J. Two identical active X chromosomes in human mammary carcinoma cells. Cancer Genet. Cytogenet. 46(2), 271-280 (1990). (Pubitemid 20178693)
32. Piao Z, Malkhosyan SR. Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosomes Cancer 33(3), 262-269 (2002). (Pubitemid 34130932)
33. Knuutila S, Aalto Y, Autio K et al. DNA copy number losses in human neoplasms. Am. J. Pathol. 155(3), 683-694 (1999). (Pubitemid 29426813)
34. Ganesan S, Silver DP, Greenberg RA et al. BRCA1 supports XIST RNA concentration on the inactive X chromosme. Cell 111(3), 393-405 (2002). (Pubitemid 35341392)
35. Richardson AL, Wang ZC, De Nicolo A et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9(2), 121-132 (2006). (Pubitemid 43202662)
36. Kristiansen M, Knudsen GP, Maguire P et al. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J. Med. Genet. 42(11), 877-880 (2005). (Pubitemid 41598198)
37. Bottarelli L, Azzoni C, Necchi F et al. Sex chromosome alterations associate with tumor progression in sporadic colorectal carcinomas. Clin. Cancer Res. 13(15 Pt 1), 4365-4370 (2007). (Pubitemid 47219701)
38. Jiang F, Richter J, Schraml P et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am. J. Pathol. 153(5), 1467-1473 (1998). (Pubitemid 28509903)
39. Mathur M, Das S, Samuels HH. PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration. Oncogene 22(32), 5031-5044 (2003). (Pubitemid 37026401)
40. Indsto JO, Nassif NT, Kefford RF, Mann GJ. Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma. Clin. Cancer Res. 9(17), 6476-6482 (2003). (Pubitemid 38031836)
41. Pizzi S, D'adda T, Azzoni C et al. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J. Pathol. 196(4), 401-407 (2002). (Pubitemid 34262851)
42. Chen YJ, Vortmeyer A, Zhuang Z, Gibril F, Jensen RT X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth. Cancer 100(7), 1379-1387 (2004). (Pubitemid 38366840)
43. D'adda T, Bottarelli L, Azzoni C et al. Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors. Mod. Pathol. 18(6), 795-805 (2005). (Pubitemid 40780513)
44. D'adda T, Candidus S, Denk H, Bordi C, Hofer H. Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions. J. Pathol. 189(3), 394-401 (1999). (Pubitemid 29489225)
45. Azzoni C, Bottarelli L, Pizzi S, D'adda T, Rindi G, Bordi C. Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas. Virchows Arch. 448(2), 119-126 (2006). (Pubitemid 43237876)
46. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021), 1199-1203 (2011).
47. Peters MA, Jarvik GP, Janer M et al. Genetic linkage analysis of prostate cancer families to Xq27-28. Hum. Hered. 51(1-2), 107-113 (2001).
48. Yaspan BL, McReynolds KM, Elmore JB, Breyer JP, Bradley KM, Smith JR. A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer. Hum. Genet. 123(4), 379-386 (2008).
49. Lange EM, Chen H, Brierley K et al. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin. Cancer Res. 5(12), 4013-4020 (1999). (Pubitemid 30013778)
50. Stephan DA, Howell GR, Teslovich TM et al. Physical and transcript map of the hereditary prostate cancer region at xq27. Genomics 79(1), 41-50 (2002). (Pubitemid 34112065)
51. Kibel AS, Faith DA, Bova GS, Isaacs WB. Xq27-28 deletions in prostate carcinoma. Genes Chromosomes Cancer 37(4), 381-388 (2003). (Pubitemid 36775780)
52. Gudmundsson J, Sulem P, Rafnar T et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 40(3), 281-283 (2008). (Pubitemid 351311771)
53. Rivera MN, Kim WJ, Wells J et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315(5812), 642-645 (2007). (Pubitemid 46214707)
54. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006). (Pubitemid 44571966)
55. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007). (Pubitemid 350134889)
56. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265), 809-813 (2009).
57. Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463 (7278), 191-196 (2010).
58. Miller RW, Young JL Jr, Novakovic B. Childhood cancer. Cancer 75 (Suppl. 1), 395-405 (1995).
59. Varan A. Wilms' tumor in children: an overview. Nephron Clin. Pract. 108(2), C83-C90 (2008). (Pubitemid 351346930)
60. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat. Rev. Cancer 5(9), 699-712 (2005). (Pubitemid 41486363)
61. Major MB, Camp ND, Berndt JD et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 316(5827), 1043-1046 (2007). (Pubitemid 46799493)
62. Rivera MN, Kim WJ, Wells J et al. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity Proc. Natl Acad. Sci. USA 106(20), 8338-8343 (2009).
63. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47(6), 461-470 (2008). (Pubitemid 351657181)
64. Perotti D, Gamba B, Sardella M et al. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 27(33), 4625-4632 (2008).
65. Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer 48(12), 1102-1111 (2009).
66. Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 28(8), 1063-1075 (2009).
67. Perotti D, Radice P. Is WTX a suitable target for cancer therapy? Pediatr. Blood Cancer 56(4), 682 (2011).
68. Jenkins ZA, Van Kogelenberg M, Morgan T et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat. Genet. 41(1), 95-100 (2009).
69. Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE, Robertson SP. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J. Med. Genet. 47(11), 791-794 (2010).
70. Chatila TA, Blaeser F, Ho N et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106(12), R75-R81 (2000). (Pubitemid 32038594)
71. Brunkow ME, Jeffery EW, Hjerrild KA et al. Disruption of a new forkhead/winged-helix protein, scurfn, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27(1), 68-73 (2001). (Pubitemid 32044521)
72. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001). (Pubitemid 32044513)
73. Wildin RS, Ramsdell F, Peake J et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27(1), 18-20 (2001). (Pubitemid 32044512)
74. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057-1061 (2003). (Pubitemid 36222930)
75. Chen GY, Chen C, Wang L, Chang X, Zheng P, Liu Y. Cutting edge: broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal infammatory diseases following in vivo depletion of FoxP3-expressing cells. J. Immunol. 180(8), 5163-5166 (2008).
76. + Tregs. J. Clin. Invest. 115(11), 3276-3284 (2005). (Pubitemid 41567592)
77. + T cells-identification of Foxp3Delta7 in human regulatory T cells. Mol. Immunol. 48(1-3), 321-332 (2010).
78. +CD28-T suppressor cells. Hum. Immunol. 65(11), 1297-1306 (2004). (Pubitemid 39535293)
79. + T-cell activation. Immunology 119(2), 203-211 (2006). (Pubitemid 44401639)
80. + regulatory T cells. Int. Immunol. 16(11), 1643-1656 (2004).
81. Ebert LM, Tan BS, Browning J et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 68(8), 3001-3009 (2008). (Pubitemid 351556301)
82. Krejsgaard T, Gjerdrum LM, Ralfkiaer E et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 22(12), 2230-2239 (2008).
83. Zhang HY, Sun H. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 287(1), 91-97 (2010).
84. Zuo T, Liu R, Zhang H et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 117(12), 3765-3773 (2007). (Pubitemid 350224087)
85. Liu R, Wang L, Chen G et al. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res. 69(6), 2252-2259 (2009).
86. Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 71(6), 2162-2171 (2011).
87. Merlo A, Casalini P, Carcangiu ML et al. FOXP3 expression and overall survival in breast cancer. J. Clin. Oncol. 27(11), 1746-1752 (2009).
88. Ladoire S, Arnould L, Mignot G et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 125(1), 65-72 (2011).
89. Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F. Human FOXP3 and cancer. Oncogene 29(29), 4121-4129 (2010).
90. Karanikas V, Speletas M, Zamanakou M et al. Foxp3 expression in human cancer cells. J. Transl. Med. 6, 19 (2008).
91. Hinz S, Pagerols-Raluy L, Oberg HH et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 67(17), 8344-8350 (2007). (Pubitemid 47395173)
92. Katoh H, Zheng P, Liu Y. Signalling through FOXP3 as an X-linked tumor suppressor. Int. J. Biochem. Cell Biol. 42(11), 1784-1787 (2010).
93. Jung DJ, Jin DH, Hong SW et al. Foxp3 expression in p53-dependent DNA damage responses. J. Biol. Chem. 285(11), 7995-8002 (2010).
94. Chan YL, Diaz JJ, Denoroy L, Madjar JJ, Wool IG. The primary structure of rat ribosomal protein L10: relationship to a Jun-binding protein and to a putative Wilms' tumor suppressor. Biochem. Biophys. Res. Commun. 225(3), 952-956 (1996). (Pubitemid 26319209)
95. Nguyen YH, Mills AA, Stanbridge EJ. Assembly of the QM protein onto the 60S ribosomal subunit occurs in the cytoplasm. J. Cell. Biochem. 68(2), 281-285 (1998). (Pubitemid 28028085)
96. Dowdy SF, Lai KM, Weissman BE, Matsui Y, Hogan BL, Stanbridge EJ. The isolation and characterization of a novel cDNA demonstrating an altered mRNA level in nontumorigenic Wilms' microcell hybrid cells. Nucleic Acids Res. 19(20), 5763-5769 (1991). (Pubitemid 21912986)
97. Van Den Ouweland AM, Verdijk M, Mannens MM, Van Oost BA. The QM gene is X-linked and therefore not involved in suppression of tumorigenesis in Wilms' tumor. Hum. Genet. 90(1-2), 144-146 (1992).
98. Monteclaro FS, Vogt PK. A Jun-binding protein related to a putative tumor suppressor. Proc. Natl Acad. Sci. USA 90(14), 6726-6730 (1993). (Pubitemid 23207286)
99. Imafuku I, Masaki T, Waragai M et al. Presenilin 1 suppresses the function of c-Jun homodimers via interaction with QM/Jif-1. J. Cell Biol. 147(1), 121-134 (1999).
100. Kaneko K, Kobayashi H, Onodera O, Miyatake T, Tsuji S. Genomic organization of a cDNA (QM) demonstrating an altered mRNA level in nontumorigenic Wilms' microcell hybrid cells and its localization to Xq28. Hum. Mol. Genet. 1(7), 529-533 (1992).
101. Oh HS, Kwon H, Sun SK, Yang CH. QM, a putative tumor suppressor, regulates proto-oncogene c-yes. J. Biol. Chem. 277(39), 36489-36498 (2002).
102. Lillico SG, Mottram JC, Murphy NB, Welburn SC. Characterisation of the QM gene of Trypanosoma brucei. FEMS Microbiol. Lett. 211(2), 123-128 (2002). (Pubitemid 34655601)
103. Stanbridge E, Farmer A, Mills A et al. Molecular characterization of QM, a novel gene with properties consistent with tumor suppressor function. Cold Spring Harb. Symp. Quant. Biol. 59, 573-576 (1994).
104. Kushner PJ, Agard DA, Greene GL et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74(5), 311-317 (2000). (Pubitemid 32126243)
105. Prall OW, Rogan EM, Sutherland RL. Estrogen regulation of cell cycle progression in breast cancer cells. J. Steroid Biochem. Mol. Biol. 65(1-6), 169-174 (1998). (Pubitemid 28335603)
106. Bamberger AM, Milde-Langosch K, Rossing E, Goemann C, Loning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J. Cancer Res. Clin. Oncol. 127(9), 545-550 (2001). (Pubitemid 32757488)
107. Horninger W, Reissigl A, Rogatsch H et al. Prostate cancer screening in Tyrol, Austria: experience and results. Eur. Urol. 35(5-6), 523-538 (1999). (Pubitemid 29229563)
108. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J. Biol. Chem. 273(48), 31853-31859 (1998). (Pubitemid 29177121)
109. Stalberg P, Grimfjard P, Santesson M et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J. Clin. Endocrinol. Metab. 89(5), 2326-2337 (2004). (Pubitemid 38619871)
110. Lejonklou MH, Edfeldt K, Johansson TA, Stalberg P, Skogseid B. Neurogenin 3 and neurogenic differentiation 1 are retained in the cytoplasm of multiple endocrine neoplasia type 1 islet and pancreatic endocrine tumor cells. Pancreas 38(3), 259-266 (2009).
111. Shen XJ, Ali-Fehmi R, Weng CR, Sarkar FH, Grignon D, Liao DJ. Loss of heterozygosity and microsatellite instability at the Xq28 and the A/G heterozygosity of the QM gene are associated with ovarian cancer. Cancer Biol. Ther. 5(5), 523-528 (2006). (Pubitemid 43765288)
112. Altinok G, Powell IJ, Che M et al. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. Prostate Cancer Prostatic Dis. 9(1), 77-82 (2006). (Pubitemid 43378874)
113. Huang S, Lee WH, Lee EY. A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product. Nature 350(6314), 160-162 (1991). (Pubitemid 21912188)
114. Guan LS, Rauchman M, Wang ZY. Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition. J. Biol. Chem. 273(42), 27047-27050 (1998). (Pubitemid 28500406)
115. Guan LS, Li GC, Chen CC, Liu LQ, Wang ZY. Rb-associated protein 46 (RbAp46) suppresses the tumorigenicity of adenovirus-transformed human embryonic kidney 293 cells. Int. J. Cancer 93(3), 333-338 (2001).
116. Chen GC, Guan LS, Yu JH, Li GC, Choi Kim HR, Wang ZY. Rb-associated protein 46 (RbAp46) inhibits transcriptional transactivation mediated by BRCA1. Biochem. Biophys. Res. Commun. 284(2), 507-514 (2001).
117. Li GC, Guan LS, Wang ZY. Overexpression of RbAp46 facilitates stress-induced apoptosis and suppresses tumorigenicity of neoplastigenic breast epithelial cells. Int. J. Cancer 105(6), 762-768 (2003).
118. Zhang TF, Yu SQ, Deuel TF, Wang ZY. Constitutive expression of Rb associated protein 46 (RbAp46) reverts transformed phenotypes of breast cancer cells. Anticancer Res. 23(5A), 3735-3740 (2003). (Pubitemid 37474318)
119. Zhang TF, Yu SQ, Loggie BW, Wang ZY. Inducible expression of RbAp46 activates c-Jun NH2-terminal kinase-dependent apoptosis and suppresses progressive growth of tumor xenografts in nude mice. Anticancer Res. 23(6C), 4621-4627 (2003). (Pubitemid 38173876)
120. Zhang TF, Yu SQ, Wang ZY. RbAp46 inhibits estrogen-stimulated progression of neoplastigenic breast epithelial cells. Anticancer Res. 27(5A), 3205-3209 (2007).
121. Li GC, Wang ZY. Retinoblastoma suppressor associated protein 46 (RbAp46) attenuates the beta-catenin/TCF signaling through up-regulation of GSK-3beta expression. Anticancer Res. 26(6B), 4511-4518 (2006).
122. Li GC, Wang ZY. Constitutive expression of RbAp46 induces epithelial-mesenchymal transition in mammary epithelial cells. Anticancer Res. 26(5A), 3555-3560 (2006).
123. Thakur A, Rahman K W, Wu J et al. Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol. Cancer Res. 5(2), 171-181 (2007). (Pubitemid 46423998)
124. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl Acad. Sci. USA 96(9), 4983-4988 (1999). (Pubitemid 29214522)
125. Wang CL, Wang CI, Liao PC et al. Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J. Proteome Res. 8(10), 4428-4440 (2009).
126. Fu J, Qin L, He T et al. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 21(2), 275-289 (2011).
127. Crea F, Hurt EM, Farrar WL. Clinical signifcance of Polycomb gene expression in brain tumors. Mol. Cancer 9, 265 (2010).
128. Tursun B, Patel T, Kratsios P, Hobert O. Direct conversion of C. elegans germ cells into specific neuron types. Science 331(6015), 304-308 (2011).
129. Yan M, Wang LC, Hymowitz SG et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 290(5491), 523-527 (2000).
130. Sabeti PC, Varilly P, Fry B et al. Genome-wide detection and characterization of positive selection in human populations. Nature 449(7164), 913-918 (2007). (Pubitemid 47598625)
131. Newton K, French DM, Yan M, Frantz GD, Dixit VM. Myodegeneration in EDA-A2 transgenic mice is prevented by XEDAR defciency. Mol. Cell. Biol. 24(4), 1608-1613 (2004). (Pubitemid 38167082)
132. Sinha SK, Zachariah S, Quinones HI, Shindo M, Chaudhary PM. Role of TRAF3 and-6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor. J. Biol. Chem. 277(47), 44953-44961 (2002). (Pubitemid 36159093)
133. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424(6950), 793-796 (2003). (Pubitemid 37021710)
134. Sinha SK, Chaudhary PM. Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism. J. Biol. Chem. 279(40), 41873-41881 (2004). (Pubitemid 39313636)
135. Tanikawa C, Ri C, Kumar V, Nakamura Y, Matsuda K. Crosstalk of EDA-A2/XEDAR in the p53 signaling pathway. Mol. Cancer Res. 8(6), 855-863 (2010).
136. Tanikawa C, Furukawa Y, Yoshida N, Arakawa H, Nakamura Y, Matsuda K. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway. Oncogene 28(34), 3081-3092 (2009).
137. Punj V, Matta H, Chaudhary PM. X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation. Clin. Cancer Res. 16(4), 1140-1148 (2010).
138. Lower KM, Turner G, Kerr BA et al. Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat. Genet. 32(4), 661-665 (2002). (Pubitemid 35435181)
139. Berland S, Alme K, Brendehaug A, Houge G, Hovland R. PHF6 deletions may cause Borjeson-Forssman-Lehmann syndrome in females. Mol. Syndromol. 1(6), 294-300 (2011).
140. Van Vlierberghe P, Palomero T, Khiabanian H et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet. 42(4), 338-342 (2010).
141. Van Vlierberghe P, Patel J, Abdel-Wahab O et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia 25(1), 130-134 (2011).
142. Yoo NJ, Kim YR, Lee SH. Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma. Acta Oncol. 51(1), 107-111 (2012).
143. Mavrakis KJ, Van Der Meulen J, Wolfe AL et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat. Genet. 43(7), 673-678 (2011).
144. Wang Q, Qiu H, Jiang H et al. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica 96(12), 1808-1814 (2011).
145. Landais S, Quantin R, Rassart E. Radiation leukemia virus common integration at the Kis2 locus: simultaneous overexpression of a novel noncoding RNA and of the proximal Phf6 gene. J. Virol. 79(17), 11443-11456 (2005). (Pubitemid 41170685)
146. Lacorazza HD, Miyazaki Y, Di Cristofano A et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 17(4), 437-449 (2002). (Pubitemid 35223533)
147. Hedvat CV, Yao J, Sokolic RA, Nimer SD. Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cells. J. Biol. Chem. 279(8), 6395-6400 (2004). (Pubitemid 38248773)
148. Seki Y, Suico MA, Uto A et al. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res. 62(22), 6579-6586 (2002). (Pubitemid 35364124)
149. Lacorazza HD, Nimer SD. The emerging role of the myeloid Elf-1 like transcription factor in hematopoiesis. Blood Cells Mol. Dis. 31(3), 342-350 (2003). (Pubitemid 37433875)
150. Totoki Y, Tatsuno K, Yamamoto S et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Genet. 43(5), 464-469 (2011).
151. Lacorazza HD, Yamada T, Liu Y et al. The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell 9(3), 175-187 (2006). (Pubitemid 43357944)
152. Yao JJ, Liu Y, Lacorazza HD et al. Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene 26(27), 4032-4037 (2007). (Pubitemid 46884297)
153. Sashida G, Liu Y, Elf S et al. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol. Cell. Biol. 29(13), 3687-3699 (2009).
154. Sashida G, Bae N, Di Giandomenico S et al. The mef/elf4 transcription factor fne tunes the DNA damage response. Cancer Res. 71(14), 4857-4865 (2011).
155. Nagasaki K, Manabe T, Hanzawa H, Maass N, Tsukada T, Yamaguchi K. Identification of a novel gene, LDOC1, down-regulated in cancer cell lines. Cancer Lett. 140(1-2), 227-234 (1999). (Pubitemid 29251335)
156. Nagasaki K, Schem C, Von Kaisenberg C et al. Leucine-zipper protein, LDOC1, inhibits NF-kappaB activation and sensitizes pancreatic cancer cells to apoptosis. Int. J. Cancer 105(4), 454-458 (2003). (Pubitemid 36578547)
157. Inoue M, Takahashi K, Niide O, Shibata M, Fukuzawa M, Ra C. LDOC1, a novel MZF-1-interacting protein, induces apoptosis. FEBS Lett. 579(3), 604-608 (2005).
158. Baffoe-Bonnie AB, Smith JR, Stephan DA et al. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Hum. Genet. 117(4), 307-316 (2005). (Pubitemid 41194557)
159. Mizutani K, Koike D, Suetsugu S, Takenawa T. WAVE3 functions as a negative regulator of LDOC1. J. Biochem. 138(5), 639-646 (2005). (Pubitemid 43058233)
160. Duzkale H, Schweighofer CD, Coombes KR et al. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood 117(15), 4076-4084 (2011).
161. Ruggero D, Grisendi S, Piazza F et al. Dyskeratosis congenita and cancer in mice defcient in ribosomal RNA modification. Science 299(5604), 259-262 (2003). (Pubitemid 36125213)
162. Yoon A, Peng G, Brandenburger Y et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 312(5775), 902-906 (2006). (Pubitemid 43727321)
163. Marrone A, Dokal I. Dyskeratosis congenita: molecular insights into telomerase function, ageing and cancer. Expert Rev. Mol. Med. 6(26), 1-23 (2004). (Pubitemid 43118239)
164. Bellodi C, Kopmar N, Ruggero D. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J. 29(11), 1865-1876 (2010).
165. Bellodi C, Krasnykh O, Haynes N et al. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res. 70(14), 6026-6035 (2010).
166. Montanaro L, Calienni M, Bertoni S et al. Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res. 70(11), 4767-4777 (2010).
167. Dummler BA, Hauge C, Silber J et al. Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J. Biol. Chem. 280(14), 13304-13314 (2005). (Pubitemid 40517216)
168. Thakur A, Sun Y, Bollig A et al. Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin. Cancer Res. 14(14), 4427-4436 (2008).
169. Lopez-Vicente L, Pons B, Coch L et al. RSK4 inhibition results in bypass of stress-induced and oncogene-induced senescence. Carcinogenesis 32(4), 470-476 (2011).
170. Lopez-Vicente L, Armengol G, Pons B et al. Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors. Clin. Cancer Res. 15(14), 4546-4553 (2009).
171. Dewdney SB, Rimel BJ, Thaker PH et al. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin. Cancer Res. 17(8), 2120-2129 (2011).
172. Braghetti A, Piazzi G, Lanfranco L, Mondello C. Multiple DNA-protein interactions at the CpG island of the human pseudoautosomal gene MIC2. Somat. Cell Molecular Genet. 19(1), 51-63 (1993). (Pubitemid 23134271)
173. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat. Immunol. 3(2), 143-150 (2002). (Pubitemid 34141444)
174. Hahn JH, Kim MK, Choi EY et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J. Immunol. 159(5), 2250-2258 (1997). (Pubitemid 127681015)
175. Manara MC, Bernard G, Lollini PL et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol. Biol. Cell. 17(4), 1910-1921 (2006). (Pubitemid 44011606)
176. Scotlandi K, Zuntini M, Manara MC et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 26(46), 6604-6618 (2007). (Pubitemid 47573680)
177. Rocchi A, Manara MC, Sciandra M et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J. Clin. Invest. 120(3), 668-680 (2010).
178. Guo Y, Yuan F, Deng H, Wang HF, Jin XL, Xiao JC. Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas. Am. J. Surg. Pathol. 35(6), 799-806 (2011).
179. Li L, Li J, Hao C et al. Immunohistochemical evaluation of solid pseudopapillary tumors of the pancreas: the expression pattern of CD99 is highly unique. Cancer Lett. 310(1), 9-14 (2011).
180. Xuan Y, Kim S, Lin Z. Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder. J. Cancer Res. Clin. Oncol. 137(1), 49-54 (2011).
181. Baker LA, Allis CD, Wang GG. PHD fngers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutat. Res. 647(1-2), 3-12 (2008).
182. De La Fuente R, Baumann C, Viveiros MM. Role of ATRX in chromatin structure and function: implications for chromosome instability and human disease. Reproduction 142(2), 221-234 (2011).
183. Villard L, Toutain A, Lossi AM et al. Splicing mutation in the ATR-X gene can lead to a dysmorphic mental retardation phenotype without alpha-thalassemia. Am. J. Hum. Genet. 58(3), 499-505 (1996). (Pubitemid 26062480)
184. Borgione E, Sturnio M, Spalletta A et al. Mutational analysis of the ATRX gene by DGGE: a powerful diagnostic approach for the ATRX syndrome. Hum. Mutat. 21(5), 529-534 (2003). (Pubitemid 36529550)
185. Nan X, Hou J, Maclean A et al. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc. Natl Acad. Sci. USA 104(8), 2709-2714 (2007). (Pubitemid 46327944)
186. Haas PS, Roy NB, Gibbons RJ et al. The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS). Br. J. Haematol. 144(4), 538-545 (2009).
187. Lugtenberg D, De Brouwer AP, Oudakker AR et al. Xq13.2q21.1 duplication encompassing the ATRX gene in a man with mental retardation, minor facial and genital anomalies, short stature and broad thorax. Am J. Med. Genet. A 149A(4), 760-766 (2009).
188. Bo H, Ghazizadeh M, Shimizu H et al. Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis. J. Nihon Med. Sch. 71(3), 172-180 (2004). (Pubitemid 38899861)
189. Coutinho-Camillo CM, Miracca EC, Dos Santos ML, Salaorni S, Sarkis AS, Nagai MA. Identification of differentially expressed genes in prostatic epithelium in relation to androgen receptor CAG repeat length. Int. J. Biol. Markers 21(2), 96-105 (2006). (Pubitemid 44210038)
190. Elsasser SJ, Allis CD, Lewis PW. Cancer. New epigenetic drivers of cancers. Science 331(6021), 1145-1146 (2011).
191. Roy D, Guida P, Zhou G, Echiburu-Chau C, Calaf GM. Gene expression profling of breast cells induced by X-rays and heavy ions. Int. J. Mol. Med. 21(5), 627-636 (2008).
192. Serrano E, Lasa A, Perea G et al. Acute myeloid leukemia subgroups identifed by pathway-restricted gene expression signatures. Acta Haematol. 116(2), 77-89 (2006). (Pubitemid 44252762)
193. Heaphy CM, De Wilde RF, Jiao Y et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333(6041), 425 (2011).
194. Yachida S, Vakiani E, White CM et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am. J. Surg. Pathol. 36(2), 173-184 (2012).
195. Schwartzentruber J, Korshunov A, Liu XY et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384), 226-231 (2012).
196. Ross MT, Grafham DV, Coffey AJ et al. The DNA sequence of the human X chromosome. Nature 434(7031), 325-337 (2005). (Pubitemid 40469169)
197. Reinius B, Shi C, Hengshuo L et al. Female-biased expression of long non-coding RNAs in domains that escape X-inactivation in mouse. BMC Genomics 11, 614 (2010).
198. Berletch JB, Yang F, Disteche CM. Escape from X inactivation in mice and humans. Genome Biol. 11(6), 213 (2010).
199. Cohen DE, Lee JT X-chromosome inactivation and the search for chromosome-wide silencers. Curr. Opin Genet. Dev. 12(2), 219-224 (2002). (Pubitemid 34219495)
200. Heard E, Disteche CM. Dosage compensation in mammals: fne-tuning the expression of the X chromosome. Genes Dev. 20(14), 1848-1867 (2006). (Pubitemid 44079323)
201. Plath K, Mlynarczyk-Evans S, Nusinow DA, Panning B. Xist RNA and the mechanism of X chromosome inactivation. Annu. Rev. Genet. 36, 233-278 (2002). (Pubitemid 36109190)
202. Csankovszki G, Nagy A, Jaenisch R. Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J. Cell Biol. 153(4), 773-784 (2001).
203. Robertson KD. DNA methylation and human disease. Nat. Rev. 6(8), 597-610 (2005). (Pubitemid 41044297)
204. Sirchia SM, Tabano S, Monti L et al. Misbehaviour of XIST RNA in breast cancer cells. PLoS ONE 4(5), E5559 (2009).
205. Busque L, Mio R, Mattioli J et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 88(1), 59-65 (1996). (Pubitemid 26230671)
206. Amos-Landgraf JM, Cottle A, Plenge RM et al. X chromosome-inactivation patterns of 1,005 phenotypically unaffected females. Am. J. Hum. Genet. 79(3), 493-499 (2006). (Pubitemid 44384258)
207. Medema RH, Burgering BM. The X factor: skewing X inactivation towards cancer. Cell 129(7), 1253-1254 (2007). (Pubitemid 46970711)
208. Kristiansen M, Langerod A, Knudsen GP, Weber BL, Borresen-Dale AL, Orstavik KH. High frequency of skewed X inactivation in young breast cancer patients. J. Med. Genet. 39(1), 30-33 (2002). (Pubitemid 34093602)
209. Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifers of BRCA1. J. Natl Cancer Inst. 100(21), 1519-1529 (2008).
210. Jazaeri AA, Chandramouli GV, Aprelikova O et al. BRCA1-mediated repression of select X chromosome genes. J. Transl. Med. 2(1), 32 (2004).
211. Silver DP, Dimitrov SD, Feunteun J et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell 128(5), 991-1002 (2007). (Pubitemid 46341424)
212. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434(7031), 400-404 (2005). (Pubitemid 40469185)
213. Liu Y, Wang Y, Li W, Zheng P. Activating transcription factor 2 and c-Jun-mediated induction of FoxP3 for experimental therapy of mammary tumor in the mouse. Cancer Res. 69(14), 5954-5960 (2009).
214. Heinze E, Baldwin S, Chan G et al. Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo. Int. J. Oncol. 35(1), 167-173 (2009).